“…Six systematic reviews 93 , 94 , 95 , 96 , 97 and 19 new RCTs 59 , 98 , 99 , 100 , 101 , 102 , 103 , 104 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 112 , 113 , 114 , 115 were newly identified in addition to the 2 prior RCTs in the 2019 ACSM Roundtable Guidelines. 116 , 117 Across the 21 RCTs, 12 studies targeted patients with breast cancer, 2 hematologic, 4 were conducted in mixed populations, and one study each focusing on head/neck/thyroid, esophageal, and prostate.…”